

# Tissue microenvironment dictates the fate and tumor-suppressive function of type 3 ILCs

Kathrin Nussbaum,<sup>1</sup> Sara H. Burkhard,<sup>1</sup> Isabel Ohs,<sup>1</sup> Florian Mair,<sup>1</sup> Christoph S.N. Klose,<sup>2</sup> Sebastian J. Arnold,<sup>3,4</sup> Andreas Diefenbach,<sup>2</sup> Sonia Tugues,<sup>1</sup> and Burkhard Becher<sup>1</sup>

<sup>1</sup>Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland

<sup>2</sup>Institute of Medical Microbiology and Hygiene and Research Centre of Immunology, University of Mainz Medical Center, Mainz, Germany

<sup>3</sup>Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine and <sup>4</sup>BIOSS Centre of Biological Signalling Studies, Albert-Ludwigs-University, Freiburg, Germany

**Innate lymphoid cells (ILCs) have been classified into “functional subsets” according to their transcription factor and cytokine profiles. Although cytokines, such as IL-12 and IL-23, have been shown to shape plasticity of ILCs, little is known about how the tissue microenvironment influences the plasticity, phenotype, and function of these cells. Here, we show clearly demarcated tissue specifications of *Rorc*-dependent ILCs across lymphoid and nonlymphoid organs. Although intestinal *Rorc* fate map-positive (*Rorc*<sup>fm+</sup>) ILCs show a clear ILC3 phenotype, lymphoid tissue-derived *Rorc*<sup>fm+</sup> ILCs acquire an natural killer (NK) cell/ILC1-like phenotype. By adoptively transferring *Rorc*<sup>fm+</sup> ILCs into recipient mice, we show that ILCs distribute among various organs and phenotypically adapt to the tissue environment they invade. When investigating their functional properties, we found that only lymphoid-tissue resident *Rorc*<sup>fm+</sup> ILCs can suppress tumor growth, whereas intestinal *Rorc*<sup>fm+</sup> ILC1s or NK cells fail to inhibit tumor progression. We thus propose that the tissue microenvironment, combined with ontogeny, provides the specific function, whereas the phenotype is insufficient to predict the functional properties of ILCs.**

## INTRODUCTION

Innate lymphoid cells (ILCs) are a growing family of innate lymphocytes with diverse phenotypic and functional properties (Spits et al., 2013). They have a critical role in various processes, such as the development of lymphoid structures, the generation and maintenance of immune homeostasis especially at mucosal sites, tissue remodeling, and the maintenance of epithelial integrity (Finke et al., 2002; Fukuyama et al., 2002; Monticelli et al., 2011; Mchedlidze et al., 2013; Goto et al., 2014). However, they have also been implicated in the control and suppression of solid tumors (Eisenring et al., 2010; Ikutani et al., 2012; Kirchberger et al., 2013; Bie et al., 2014; Chan et al., 2014; Carrega et al., 2015; Crome et al., 2017; Irshad et al., 2017).

Group 1 ILCs include NK cells and other non-NK ILC1 cells, all expressing the transcription factor T-bet and secreting IFN- $\gamma$  when stimulated with IL-12, IL-15, or IL-18 (Fuchs and Colonna, 2013; Klose et al., 2014). Despite their similarities to NK cells in transcription factor profiles and cytokine expression, the role of ILC1s in tumor surveillance remains to be established. ILC2s produce type 2 cytokines, such as IL-5 and IL-13, and have been implicated in both tumor surveillance and tumorigenesis. Thus, whereas induc-

tion of IL-13 by IL-33 in ILC2s promotes tumor growth in two distinct mouse models (Jovanovic et al., 2014; Li et al., 2014), anti-tumor activity against lung metastasis requires IL-5 production by ILC2s (Ikutani et al., 2012).

Genetic fate mapping identifies type 3 ILCs by the expression of retinoic acid-receptor-related orphan receptor (ROR) $\gamma$ t during their emergence (Eberl and Littman, 2004). These ILC3s include C-C chemokine receptor (CCR)6<sup>+</sup> ILC3s (mainly representing lymphoid tissue inducer cells [LTi<sup>s</sup>]), CCR6<sup>-</sup> natural cytotoxicity receptor (NCR)<sup>+</sup> ILC3s, and CCR6<sup>-</sup>NCR<sup>-</sup> ILC3s (Klose et al., 2013). ILC3s have also been reported to have pro- or antitumorogenic effects in different experimental setups. They were shown to promote bacteria-induced colon cancers in an IL-22-dependent manner, and IL-23 stimulation induces de novo development of intestinal adenomas (Kirchberger et al., 2013; Chan et al., 2014). In contrast, type 3 ILCs have been implicated in tumor suppression in a model of malignant melanoma (Eisenring et al., 2010). In that particular study, IL-12 was responsible for the tumor-suppressive capacity of *Rorc*<sup>fm+</sup> ILCs (Eisenring et al., 2010). The tumor-suppressive cytokine IL-12 was previously described to promote T-bet expression resulting in the loss of ROR $\gamma$ t-inducing so-called “ex-ILC3s,” which are phenotypically similar to ILC1s (Vonarbourg et al., 2010). In addition, IL-12 induces a reversible differentiation of human

Correspondence to Burkhard Becher: becher@immunology.uzh.ch

Abbreviations used: CCL, c-c chemokine ligand; CCR, c-c chemokine receptor; CXCR, C-X-C chemokine receptor; ILC, innate lymphoid cell; LTi, lymphoid tissue inducer cell; NCR, natural cytotoxicity receptor; NGS, next-generation sequencing; PCA, principal component analysis; ROR, retinoic acid-receptor-related orphan receptor; siLP, small intestinal lamina propria; t-SNE, t-stochastic neighbor embedding.

© 2017 Nussbaum et al. This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see <http://www.rupress.org/terms/>). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 4.0 International license, as described at <https://creativecommons.org/licenses/by-nc-sa/4.0/>).






Figure 1. ILCs reside in various tissues and *Rorc<sup>fm+</sup>* ILCs from spleen and small intestine cluster in demarcated cluster sets. (A) Flow cytometric analysis to identify *Rorc<sup>fm+</sup>* ILCs in various organs of *Rorc<sup>fm+</sup>-Rag1<sup>-/-</sup>* mice, including lymphoid organs, such as skin-draining LNs (sdLN), mesenteric LNs (mLN), spleen (spl), and thymus as well as nonlymphoid organs, such as the liver, lung, siLP, and skin in a steady state. Representative graphs of two independent experiments,  $n \geq 4$  each. (B) Total counts of *Rorc<sup>fm+</sup>* ILCs within the CD45 compartment of various organs of *Rorc<sup>fm+</sup>-Rag1<sup>-/-</sup>* mice (skin represents total counts of two ears). Graphs represent pooled data from two independent experiments,  $n \geq 4$  each (means  $\pm$  SEM). (C) Histogram overlay of splenic

intestinal ILC3s and ILC2 cells into type 1–like ILCs under inflammatory conditions (Bernink et al., 2015; Bal et al., 2016; Lim et al., 2016; Ohne et al., 2016; Silver et al., 2016). Besides the nonredundant role of this cytokine in the plasticity of ILC subsets, little is known about the role of the tissue microenvironment in delineating phenotypic and functional ILC fate. Therefore, whether the functional ILC fate is shaped not only during its lineage commitment but also by the tissue microenvironment is currently unclear.

By systematically interrogating one functional property of tissue-resident ILCs, namely IL-12–mediated tumor-suppressive capacity, we observed that the specific tissue microenvironment determines the fate and function of distinct *Rorc*<sup>fm+</sup> ILCs subtypes. Intestinal *Rorc*<sup>fm+</sup> ILCs predominantly retained expression of ROR $\gamma$ t, whereas progeny of the same precursor migrating into lymphoid tissues up-regulated T-bet and acquired potent tumor-suppressive properties. We thus propose that the individual tissue microenvironment shapes the functional specialization of ILCs. Of note, conventional NK cells and bona fide ILC1s, despite being highly responsive to IL-12, did not have tumor-suppressive activity, suggesting that tissue microenvironment-induced plasticity combined with ontogeny and early transcriptional imprinting determines ILC function.

## RESULTS

### *Rorc*<sup>fm+</sup> ILCs reside in various tissues and adapt to the local microenvironment

ILC3s express the transcription factor ROR $\gamma$ t and regulate various immune responses, most prominently within the intestinal tract (Sanos et al., 2009; Mortha et al., 2014; Bernink et al., 2015; Hepworth et al., 2015). Other than barrier-tissue immunity and their role in lymphoid organogenesis, little is known about the prevalence and function of ROR $\gamma$ t-dependent ILCs. Therefore, we characterized the progeny of ROR $\gamma$ t-dependent ILC precursors in various lymphoid and nonlymphoid tissues in steady state with multiparametric flow-cytometry analysis (Fig. 1 A). We took advantage of genetic fate mapping using *Rorc*-Cre<sup>Tg</sup>; *Rosa26R*<sup>eYFP/+</sup> mice (from now on referred to as *Rorc*<sup>fm</sup> mice; Eberl and Littman, 2004), in which all cells that expressed ROR $\gamma$ t at any time during their development, as well as in their progeny, are permanently marked with YFP (hereafter, called *Rorc*<sup>fm+</sup> cells). By crossing *Rorc*<sup>fm</sup> mice onto a *Rag1*<sup>-/-</sup> background, we eliminated all canonical fate-mapped cells (i.e., T lymphocytes) and exclusively labeled TCR-negative *Rorc*<sup>fm+</sup> ILC. The frequencies and total

cell numbers of *Rorc*<sup>fm+</sup> ILCs in steady state were expectedly highest in the small intestine (Fig. 1, A and B; and Fig. S1, A and B). However, we found significant numbers of *Rorc*<sup>fm+</sup> ILCs in the thymus and secondary lymphoid organs as well, including skin-draining LNs, mesenteric LNs, and spleen, and in nonlymphoid organs, such as liver, lung, and skin.

To further characterize *Rorc*<sup>fm+</sup> ILCs of distinct tissues, we performed phenotypic profiling with ILC and NK cell markers, revealing vast differences in *Rorc*<sup>fm+</sup> ILCs of various organs, in particular, between lymphoid and nonlymphoid tissues (Fig. S1 C). We chose a representative lymphoid tissue (i.e., spleen) and nonlymphoid tissue (i.e., small intestinal lamina propria [siLP]) for further detailed analysis (Fig. 1 C). Lymphoid tissue-resident *Rorc*<sup>fm+</sup> ILCs express high levels of NK cell-associated markers, such as NKp46, NK1.1, and CD49b and, thus, phenotypically resemble NK cells, even though they clearly arise from a distinct lineage (as defined by *Rorc*<sup>fm</sup>). In contrast, intestinal *Rorc*<sup>fm+</sup> ILCs homogeneously express IL-7R $\alpha$  and Thy1.2, heterogeneously express NKp46, but are mostly negative for NK1.1 and CD49b (Fig. 1 C).

Numerous lineage-defining markers for the different ILC subsets have been proposed, with some degree of uncertainty as to whether each subset represents a stable lineage (Spits et al., 2013). Given the apparent heterogeneity and/or plasticity, we decided to use a computer-aided clustering approach for the unsupervised identification of distinct fates and phenotypes of ROR $\gamma$ t-dependent ILCs. Therefore, CD45<sup>+</sup>*Rorc*<sup>fm+</sup> ILCs of spleen and siLP—without any further pre-gating—were fed into the dimensionality reduction algorithm t-stochastic neighbor embedding (t-SNE), followed by analysis of the combined data sets with flowSOM ( $k = 5$ ). Strikingly, the unsupervised clustering separated splenic and siLP *Rorc*<sup>fm+</sup> ILCs into clearly demarcated cluster sets (Fig. 1 D). Although almost all siLP *Rorc*<sup>fm+</sup> ILCs grouped together in one separate cluster (cluster 4), splenic ILCs were split into 4 clusters (cluster 1–3 and 5), indicating greater diversity among splenic subsets of type 3 ILCs compared with siLP ILC3s.

As shown previously (Fig. 1 C), siLPs (represented in cluster 4) express mainly ILC3-associated markers (Fig. 1, E and F). The splenic ILC clusters could be matched to previously described ILC3 subsets. Cluster 1 represents so-called CCR6<sup>-</sup>NCR<sup>+</sup> ILC3s (Klose et al., 2013), whereas cluster 3 resembles CCR6<sup>+</sup> ILCs (Klose et al., 2013). Because of the high expression of NK cell markers and the low expression of ILC3-associated markers, cluster 2 may represent “ex-ILC3s,” whereas cells of cluster 5 may hold LTi-like cells express-

(spl) *Rorc*<sup>fm+</sup> ILCs (black continuous line), siLP *Rorc*<sup>fm+</sup> ILCs (gray continuous line), and splenic (spl) *Rorc*<sup>fm-</sup> NK cells (dotted line). Representative histograms of four independent experiments,  $n \geq 5$  each. (D) Dimensionality reduction using t-SNE. Data from  $4 \times 10^4$  *Rorc*<sup>fm+</sup> ILCs of spleen and siLP (gated on live, single CD45<sup>+</sup>*Rorc*<sup>fm+</sup> ILCs) were transformed and plotted in two t-SNE dimensions using R software. Clustering was performed using the flowSOM algorithm ( $k = 5$ ). Depicted are the combined spleen and siLP data sets (left), the siLP data set only (middle), and the spleen data set only (right). (E) ILC3-associated and NK cell-associated markers plotted in a heat map across flowSOM clusters from D. (F) Expression pattern of ILC3-associated and NK cell-associated markers depicted in the two t-SNE dimensions.




Figure 2. **The tissue microenvironment dictates the fate of *Rorc*<sup>flm</sup> ILCs.** (A) Schematic representation of the experimental setup. *Rorc*<sup>flm</sup> ILCs from spleen (spl) or siLP of *Rorc*<sup>flm</sup>-*Rag1*<sup>-/-</sup> mice were isolated using flow cytometric cell sorting and adoptively transferred into lymphopenic *Rag2*<sup>-/-</sup>*Il2rg*<sup>-/-</sup> mice. After 5 wk, various organs were analyzed. (B) Distribution of adoptively transferred *Rorc*<sup>flm</sup> ILCs of splenic (spl, top) and siLP (bottom) origin, homing to various organs (clockwise: liver, blood, spleen, siLP, or lung) within *Rag2*<sup>-/-</sup>*Il2rg*<sup>-/-</sup> mice. Graphs represent pooled data from three independent experiments,

ing IL-7R $\alpha$ , low levels of c-Kit, Sca-1, and CCR6 (compare CCR6 expression map of Fig. 1 F), but no NK cell markers. Of note, similar splenic *Rorc*<sup>fm+</sup> ILCs clusters were found regardless of whether they were analyzed in WT or *Rag*-deficient mice (Fig. S1, D–F). These data reveal the distinct characteristics of splenic *Rorc*<sup>fm+</sup> ILCs and siLP *Rorc*<sup>fm+</sup> ILCs, despite sharing the same lineage, and suggest a phenotypic specialization of *Rorc*<sup>fm+</sup> ILCs driven by the tissue microenvironment.

### The tissue microenvironment determines the fate of type 3 ILCs

Whether the phenotypic specialization of *Rorc*<sup>fm+</sup> ILCs from various organs is stable over time or whether these phenotypes are plastic and imprinted by the local tissue microenvironment is a matter of speculation. To interrogate the plasticity of type 3 ILCs, we adoptively transferred *Rorc*<sup>fm+</sup> ILCs isolated from various organs into *Rag2*<sup>-/-</sup>*Il2rg*<sup>-/-</sup> mice, allowing tissue homing akin to the homeostatic expansion of T lymphocytes in a lymphopenic environment (Fig. 2 A). Regardless of the tissue from which the *Rorc*<sup>fm+</sup> ILCs were isolated, they stochastically homed to various organs. *Rorc*<sup>fm+</sup> ILCs isolated, for example, from the spleen did not “home” specifically into the spleen but were similarly disseminated across all examined organs. Conversely, *Rorc*<sup>fm+</sup> ILCs isolated from the small intestine, likewise, colonized lymphoid and nonlymphoid organs, without the predisposition to home into the gut (Fig. 2 B). Importantly, the phenotypic properties and expression of lineage markers of adoptively transferred *Rorc*<sup>fm+</sup> ILCs depended on the local tissue environment they encountered and not on their origin (Fig. 2 C). In other words, *Rorc*<sup>fm+</sup> ILCs colonizing the spleen expressed NK cell-associated markers (Fig. 2 C); *Rorc*<sup>fm+</sup> ILCs colonizing the small intestine adopted the phenotype of ILC3s by expressing, for example, Thy1.2 but no NK cell-associated markers (Fig. 2 C). To investigate whether this phenomenon was caused by selective migration (and/or survival) of a stable subpopulation or was indeed stochastic, we sorted NCR<sup>+</sup> ILC1-like (NKp46<sup>+</sup>NK1.1<sup>+</sup>*Rorc*<sup>fm+</sup> ILCs) or NCR<sup>-</sup>ILC3s (NKp46<sup>-</sup>NK1.1<sup>-</sup>*Rorc*<sup>fm+</sup> ILCs) cells and adoptively transferred them into *Rag2*<sup>-/-</sup>*Il2rg*<sup>-/-</sup> mice. As with unfractionated *Rorc*<sup>fm+</sup> ILCs, we found no clear homing preferences of the purified subsets but observed a distribution across various organs (Fig. 2 D). Moreover, both subpopulations changed their phenotypes according to the organs they encountered, thus favoring the notion of site-specific, plastic behavior over selective migration or survival of a specific ILC subset.

Taken together, these results reveal that the tissue microenvironment in the steady state provides strong guidance cues for the phenotypic adaptation of ILCs to the individual tissue. This raises the question of whether the phenotypic changes driven by the tissue microenvironment also translate into functional differences regarding cytokine responsiveness and tumor protection.


### The tissue microenvironment dictates the function of *Rorc*<sup>fm+</sup> ILCs

To evaluate functional differences of *Rorc*<sup>fm+</sup> ILCs originating from either a lymphoid or nonlymphoid environment, we investigated the capacity of these cells to modulate melanoma growth in the context of the tumor-suppressive cytokine IL-12. We engineered B16.F10 melanoma cells to constitutively express a recombinant IL-12:Fc fusion protein or an Fc-tag alone (hereafter, called B16-IL-12 vs. B16-ctrl; Eisenring et al., 2010; vom Berg et al., 2013) and cotransplanted these cells with *Rorc*<sup>fm+</sup> ILCs s.c. into *Il12rb2*<sup>-/-</sup> mice. In this particular setting, *Rorc*<sup>fm+</sup> ILCs comprise the only IL-12-responsive cell type in the tumor (Fig. 3 A). Small numbers of lymphoid tissue-derived *Rorc*<sup>fm+</sup> ILCs were able to suppress tumor growth over an extended period (Fig. 3 B). In contrast, *Rorc*<sup>fm+</sup> ILCs originating from the siLP failed to reject tumors, suggesting that their conditioning in the gut microenvironment stunted their tumor-suppressive capacity. Conventional NK cells also failed to reject B16-IL-12 melanomas, despite their phenotypic similarity to splenic *Rorc*<sup>fm+</sup> ILCs (Fig. 3, B and C). Tumor suppression by splenic ILC3s resulted in extended survival (Fig. 3 D). Of note, LN-derived *Rorc*<sup>fm+</sup> ILCs possessed tumor-suppressive capacity, whereas hepatic *Rorc*<sup>fm+</sup> ILCs, similar to siLP *Rorc*<sup>fm+</sup> ILCs, did not induce tumor suppression (Fig. S2, A and B). To assess whether our observations resulted from the lymphopenic environment in *Rag*<sup>-/-</sup> mice, we confirmed our findings using *Rorc*<sup>fm+</sup> ILCs from WT mice: splenic *Rorc*<sup>fm+</sup> ILCs retain tumor-suppressive properties, whereas neither siLP *Rorc*<sup>fm+</sup> ILCs nor phenotypically similar *Rorc*<sup>fm-</sup> NK cells inhibit tumor growth (not depicted). Our data suggest both phenotypic and functional specialization of tissue-resident *Rorc*<sup>fm+</sup> ILCs. Thus, the function of ILCs is shaped not only during their lineage commitment but also by the tissue microenvironment.

### Tumor-suppressive *Rorc*<sup>fm+</sup> ILCs down-regulate ROR $\gamma$ t and increase T-bet expression

Previously, IL-23 receptor expression was reported on ILC3s, whereas IL-12 receptor expression was restricted to ILC1s

*n*  $\geq$  3 each. (C) Flow cytometric analysis of live, single, CD45<sup>+</sup>*Rorc*<sup>fm+</sup> ILCs originating from spleen (spl, top) or siLP (bottom) after 5 wk of expansion in *Rag2*<sup>-/-</sup>*Il2rg*<sup>-/-</sup> mice. Graphs represent pooled data from three independent experiments, *n*  $\geq$  3 each. (D) Distribution of adoptively transferred highly purified splenic NCR<sup>+</sup> (NKp46<sup>+</sup>NK1.1<sup>+</sup>) *Rorc*<sup>fm+</sup> ILCs (top) and NCR<sup>-</sup> (NKp46<sup>-</sup>NK1.1<sup>-</sup>) siLP *Rorc*<sup>fm+</sup> ILCs (bottom), homing to various organs (clockwise: liver, blood, spleen, siLP, or lung) within *Rag2*<sup>-/-</sup>*Il2rg*<sup>-/-</sup> mice. Graphs represent pooled data from two to five independent experiments, *n*  $\geq$  5. (E) Flow cytometric analysis of spleen-derived NCR<sup>+</sup>*Rorc*<sup>fm+</sup> ILCs (top) or siLP-derived NCR<sup>-</sup>*Rorc*<sup>fm+</sup> ILCs (bottom) after 5 wk of expansion in *Rag2*<sup>-/-</sup>*Il2rg*<sup>-/-</sup> mice (gated on live, single, CD45<sup>+</sup> *Rorc*<sup>fm+</sup> ILCs). Representative histograms from two to five independent experiments, *n*  $\geq$  5.



**Figure 3. Splenic *Rorc*<sup>flm+</sup> ILCs suppress tumor growth in an IL-12-dependent manner.** (A) Schematic representation of the experimental setup. B16-IL-12 tumor cells were s.c. injected into *Il12rb2*<sup>-/-</sup> mice with or without *Rorc*<sup>flm+</sup> ILCs, isolated from various organs of *Rorc*<sup>flm+</sup>-*Rag1*<sup>-/-</sup> mice using flow cytometric cell sorting. (B) Tumor growth of B16-IL-12 tumor cells coinjected with splenic (spl) *Rorc*<sup>flm+</sup> ILCs (open circles), siLP *Rorc*<sup>flm+</sup> ILCs (open squares), or splenic (spl) *Rorc*<sup>flm+</sup> NK cells (closed squares), respectively, or in the absence of ILCs (closed circles) over time. For comparison of the tumor growth curve two-way ANOVA with Tukey's multiple comparisons test was used. \*\*\*, *P* < 0.001. (C) Quantification of tumor growth at d 24 after tumor inoculation. One-way ANOVA with Tukey's multiple comparisons test was performed. \*\*\*, *P* < 0.001. (D) Kaplan-Meier survival curve of mice coinjected with B16-IL-12 and splenic (spl) *Rorc*<sup>flm+</sup> ILCs (bold continuous line), siLP *Rorc*<sup>flm+</sup> ILCs (gray continuous line), splenic (spl) *Rorc*<sup>flm+</sup> NK cells (gray dashed line), or in the absence of ILCs (bold dotted line). (B-D). Graphs represent pooled data from three independent experiments, *n* ≥ 4 each (means ± SEM). For comparison of survival curves, a Lox-rank (Mantel-Cox) test was used. \*, *P* < 0.05; \*\*, *P* < 0.01; \*\*\*, *P* < 0.001.


(Vonarbourg et al., 2010). To determine whether the tissue influences, which render the tumor-suppressive function of *Rorc*<sup>flm+</sup> ILCs also alter their responsiveness toward IL-12/IL-23, we quantified the expression of IL-12/IL-23 receptors on isolated *Rorc*<sup>flm+</sup> ILCs from spleen and siLP. Splenic *Rorc*<sup>flm+</sup> ILCs expressed higher levels of the IL-12-specific receptor subunit *Il12rb2* compared with siLP *Rorc*<sup>flm+</sup> ILCs, which expressed the *Il23r* (Fig. 4 A). Thus, the heightened sensitivity of splenic *Rorc*<sup>flm+</sup> ILCs to IL-12 may explain their tumor-suppressive capacity.

A previous study suggested an inverse correlation between IL-12 receptor and RORγt expression in *Rorc*<sup>flm+</sup> ILCs (Vonarbourg et al., 2010). To evaluate whether the tissue microenvironment directly influences RORγt expression, we took advantage of the *Rorc*<sup>flm</sup> (*Rorc*<sup>flm+</sup> ILCs) and *Rorc*-reporter (*Rorc*<sup>rep+</sup> ILCs) mice and compared their ILC3 compartment of spleen and siLP. Although the small intestine was rich in both *Rorc*<sup>flm+</sup> and *Rorc*<sup>rep+</sup> ILCs, most splenic *Rorc*<sup>flm+</sup> ILCs lost RORγt expression (Fig. 4 B). Ac-

cordingly, most splenic ILC3s expressed T-bet uniformly and the cytokines IFN-γ, GM-CSF (Fig. 4, C-E), granzyme, and perforin (not depicted), thus corroborating a shift of tumor-suppressive *Rorc*<sup>flm+</sup> ILCs toward type 1 immunity.

**IL-12 activates the tumor microenvironment and the recruitment of tumor-invading ILCs**

To assess the effect of IL-12 on the tumor microenvironment and how that influences ILC-driven immune responses, we injected B16-control or B16-IL-12 s.c. into C57BL/6 or IL-12-unresponsive *Il12rb2*<sup>-/-</sup> mice (Fig. 5 A). On day 5 after transplantation, the complete tumor tissue was resected, and total mRNA was analyzed by next-generation sequencing (NGS). Fig. 5 B depicts the signature of the tumor microenvironment in the presence or absence of IL-12. Increased expression of both IL-12 subunits, STAT4 and IFN-γ, confirmed the IL-12 responsiveness of the tumor microenvironment at early times (not depicted). IL-12 expression induced a signa-



**Figure 4. Splenic *Rorc<sup>flm+</sup>* ILCs acquire an "ex-ILC3" phenotype.** (A) Normalized expression of *Il12rb2* and *Il23r* mRNA levels of flow cytometric-sorted splenic and siLP *Rorc<sup>flm+</sup>* ILCs. Graphs represent pooled data from three independent experiments,  $n = 3$  each (means  $\pm$  SEM). Two-tailed unpaired  $t$  test was performed. \*,  $P < 0.05$ . (B, left) Schematic representation of *Rorc<sup>flm+</sup>-Rag1<sup>-/-</sup>* and reporter *Rorc<sup>GFP</sup>-Rag1<sup>-/-</sup>* mice. (Right) Flow cytometric analysis of splenic and siLP ILCs in reporter (left; GFP) and fm (right; YFP) mice. Representative graphs of three independent experiments,  $n \geq 4$  each. (C) Histogram overlay of transcription factors expressed by splenic (spl) *Rorc<sup>flm+</sup>* ILCs (bold continuous line), siLP *Rorc<sup>flm+</sup>* ILCs (gray continuous line), or splenic (spl) *Rorc<sup>flm+</sup>* NK cells (dotted line). Representative histograms of three independent experiments,  $n = 4$  each. (D) Quantification of RORyt- or T-bet-expressing splenic (spl) or siLP *Rorc<sup>flm+</sup>* ILCs. Graphs represent pooled data from three independent experiments,  $n = 4$  each (means  $\pm$  SEM). Two-tailed, unpaired  $t$  test was performed. \*,  $P < 0.05$ ; \*\*\*,  $P < 0.001$ . (E, left) Flow cytometric analysis of cytokine expression by splenic (spl) or siLP *Rorc<sup>flm+</sup>* ILCs. Representative histograms of three independent experiments,  $n = 4$  each. (Right) Quantification of cytokine expressing splenic (spl) or siLP *Rorc<sup>flm+</sup>* ILCs. Graphs represent pooled data from three independent experiments,  $n \geq 3$  each (means  $\pm$  SEM). One-way ANOVA with Tukey's multiple comparisons test was performed. \*,  $P < 0.05$ ; \*\*\*,  $P < 0.001$ .

ture in the tumor microenvironment reminiscent of type 1 immune responses, as shown by strong up-regulation of IFN- $\gamma$ , the FAS ligand, and the type 1-associated chemokine receptors C-X-C chemokine receptor (CXCR)6, CCR5, CXCR3, and CCR1 (Fig. 5 C). Additionally, several chemokines, such as C-C chemokine ligand (CCL)2, CCL4, CCL7, CCL8, and CCL12, known to attract/recruit lymphocytes, monocytes, and a variety of other im-

mune cells were up-regulated in the presence of IL-12 (Fig. 5 D). Taken together, the pro-inflammatory responses induced by IL-12 may support the invasion and activation of ILCs into the tumor tissue.

We next investigated whether the effect of IL-12 on the tumor microenvironment would indeed favor the recruitment of tumor-suppressive *Rorc<sup>flm+</sup>* ILCs. We found significantly elevated frequencies of *Rorc<sup>flm+</sup>* ILCs in IL-12-treated tumors




Figure 5. **IL-12 alters the tumor microenvironment and increases the frequency of tumor-infiltrating *Rorc<sup>f/m+</sup>* ILCs.** (A) Schematic representation of the three experimental groups used for NGS: B16-control (ctrl) tumor cells were injected into WT mice and B16-IL-12 tumor cells into WT or *Il12rb2<sup>-/-</sup>* mice, respectively. NGS was performed on RNA obtained from tumors 5 d after tumor inoculation. (B) Heat map of differentially expressed genes in the tumor tissue. (C) Heat map of expression levels of Th1- and Th2-associated genes of B16-IL-12 in WT mice (means of three tumors depicted). (D) Normalized counts of the chemokines *Ccl2*, *Ccl4*, *Ccl7*, *Ccl8*, and *Ccl12*. Each data point represents one tumor (means ± SEM). One-way ANOVA with Tukey's



compared with controls (Fig. 5, E and F). Similar to lymphoid tissue-resident  $Rorc^{fm+}$  ILCs, tumor-infiltrating  $Rorc^{fm+}$  ILCs mostly expressed Thy1.2, but also the markers NKp46, NK1.1, and CD49b, classifying them as phenotypically similar to NK cells (Fig. 5 G). Our data show that the presence of IL-12 supports the recruitment of ILCs, which resemble tumor-suppressive, lymphoid tissue-resident  $Rorc^{fm+}$  ILCs.

### ILC1s resemble tumor-suppressive $Rorc^{fm+}$ ILCs but fail to suppress tumor growth

Previous studies demonstrated the plastic nature of ILCs, in particular the conversion of ILC3 toward type 1 ILC polarization (Vonarbourg et al., 2010; Klose et al., 2013, 2014; Bernink et al., 2015). Because we found that tumor-suppressive  $Rorc^{fm+}$  ILCs acquire a phenotype similar to type 1 ILCs (losing ROR $\gamma$ t and expressing NCRs), we evaluated the capacity of the phenotypically similar  $Eomes^{-}$  ILC1s to suppress tumor growth in an IL-12-dependent manner.

We made use of a recently introduced mouse model, combining the *fm* of *Rorc* with the reporter for *Eomes* ( $Eomes^{GFP+}$ ; Klose et al., 2014), allowing for the identification of conventional NK cells ( $Rorc^{fm-}Eomes^{+}$ ), ILC1s ( $Rorc^{fm-}Eomes^{-}$ ) and ILC3s ( $Rorc^{fm+}$ ) by their transcription profile and ontogeny tracing (Fig. 6 A and Fig. S3, A and B). When characterizing the splenic ILC compartment,  $Eomes^{+}$  NK cells clearly dominate in numbers, comprising ~50% of all CD45<sup>+</sup>lin<sup>-</sup> cells and almost 80% of the splenic ILC1 and ILC3 compartment (Fig. 6 B), in comparison to  $Eomes^{-}$  ILC1s or  $Rorc^{fm+}$  ILCs, which represent 18% or 4%, respectively, of the ILC compartment (Fig. 6 B). As previously observed (Klose et al., 2014),  $Eomes^{-}$  ILC1s showed a heterogeneous expression pattern of Thy1.2 and IL-7R $\alpha$  (Fig. 6 C), expressed T-bet and were negative for ROR $\gamma$ t and *Eomes*, as confirmed by intracellular staining (not depicted). Thus,  $Eomes^{-}$  ILC1s clearly show a type 1 phenotype resembling that of most lymphoid tissue-resident  $Rorc^{fm+}$  ILCs, raising the question as to whether they also have tumor-suppressive properties.

We challenged *Il12rb2*<sup>-/-</sup> mice with B16-IL-12 tumor cells infused with one of the respective splenic ILC subsets (for schematic representation of the experimental setup, see Fig. 3 A). Despite the phenotypic similarities and the same tissue origin as  $Rorc^{fm+}$  ILCs,  $Eomes^{-}$  ILC1s failed to suppress tumor growth (Fig. 6, D and E), pointing out an essential role of the ontogeny for defining their function. Taken together, the type 1 phenotype in lymphoid tissues applies to  $Eomes^{-}$  ILC1s, conventional  $Eomes^{+}$  NK cells and  $Rorc^{fm+}$

ILCs, of which only the latter ones are tumor-suppressive in response to the proinflammatory cytokine IL-12.


To further explore the differences between tumor-suppressive and nonsuppressive ILCs, we performed transcriptome analysis of splenic  $Rorc^{fm+}$  ILCs,  $Eomes^{-}$  ILC1s and  $Eomes^{+}$  NK cells, as well as siLP  $Rorc^{fm+}$  ILCs. Compellingly, principle component analysis (PCA) shows similarity between splenic  $Rorc^{fm+}$  ILCs and  $Eomes^{-}$  ILC1s. Component 3 separates splenic  $Rorc^{fm+}$  ILC3s from the other ILC subsets, indicating that differentially expressed genes in this population may be involved in their functional differences in tumor suppression (Fig. 6 F). Basic hierarchical clustering of the four populations showed that splenic and siLP  $Rorc^{fm+}$  ILCs were more closely related to each other compared with the type 1 ILCs, despite them being isolated from two distinct organs, reflecting the strong guidance cues of their common cellular derivation (Fig. 6 G and Fig. S4, A–D). Further in-depth analysis revealed that wide ranges of cellular mechanisms are significantly altered in tumor-suppressive splenic  $Rorc^{fm+}$  ILCs compared with all the other analyzed ILC subsets. Differences in leukocyte cell–cell adhesion and leukocyte-activation pathways, including the greater expression of genes such as *Ccr7*, *Cxcr5*, *Cd4*, *Cd81*, and *Erb2* hints toward a distinct migration and homing mechanisms of splenic  $Rorc^{fm+}$  ILCs in response to malignancies. Similarly, genes involved in the cytokine-mediated signaling pathways and cellular proliferation (*Krt8*, *Tnfrsf11a* [encoding RANK, i.e., TRANCE], and *Adm*, *Cd81*, *Erb2*, *Wisp2*, or *Marveld3*) are altered, pointing toward distinct functionality of splenic  $Rorc^{fm+}$  ILCs. Similar to previously published studies, genes involved in the pathway of LN development were differentially expressed in splenic  $Rorc^{fm+}$  ILCs, confirming the validity of the approach (Fig. S4 E). Taken together, tumor-suppressive splenic  $Rorc^{fm+}$  ILCs possess transcriptional differences compared with nonsuppressive siLP  $Rorc^{fm+}$  ILCs or other splenic type 1 ILCs, which may explain their differential functionality. Thus, the classification of ILC subsets based on their superficial phenotypic appearance, that is, surface markers alone, seems arbitrary in light of their function and signature being guided primarily by their ontogeny (i.e., transcriptional regulation) and the tissue they reside in.

### Splenic $Rorc^{fm+}$ ILCs change the tumor microenvironment, favoring leukocyte invasion

The mechanism by which IL-12-activated  $Rorc^{fm+}$  ILCs suppress tumor growth remains unknown. The fact that  $Rorc^{fm+}$  ILCs only express low amounts of cytotoxic mol-

---

multiple comparisons test was performed. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ . (E) Flow cytometric analysis of live, single CD45<sup>+</sup>  $Rorc^{fm+}$  ILCs in the tumor tissue (growing in  $Rorc^{fm-}Rag1^{-/-}$  mice) 5 d after tumor inoculation. (F) Frequencies of tumor-infiltrating  $Rorc^{fm+}$  ILCs within the CD45 compartment 5 d after tumor inoculation in the presence or absence of intratumorally administered IL-12. Representative graph of one of three independent experiments,  $n \geq 3$  each (means  $\pm$  SEM). Two-tailed, unpaired *t* test was used. \*,  $P < 0.05$ . (G) Histogram overlay of  $Rorc^{fm+}$  ILCs of tumor (dotted line), spleen (spl, bold continuous line), and siLP (gray continuous line) 5 d after tumor inoculation into  $Rorc^{fm-}Rag1^{-/-}$  mice. Representative histograms from three independent experiments,  $n = 5$  each.



**Figure 6. ILC1s phenotypically resemble tumor-suppressive *Rorc<sup>tm</sup>* ILCs but fail to inhibit tumor growth.** (A) Schematic representation of the *Rorc<sup>cre</sup>* mice crossed to the *Eomes<sup>GFP</sup>-Rosa26R<sup>eYFP/+</sup>* mice labeling all cells expressing RORγt with enhance YFP and all cells expressing *Eomes* with GFP. (B, left) Quantification of the different ILC subsets within the CD45<sup>+</sup> compartment of the spleen. (Right) Distribution of NK cells (dark bar), ILC1s (light bar), and ILC3s (white bar) within the ILC compartment of the spleen. Graphs represent pooled data from two independent experiments, *n* ≥ 5 each (means ± SEM). (C) Histogram overlay of different ILC subsets in the spleen. Representative histograms of two independent experiments, *n* ≥ 5 each.

ecules, compared with NK cells or ILC1s (Fig. S5 A), and suppression of B16–IL-12 tumors is perforin independent (Eisenring et al., 2010) led us to hypothesize that *Rorc*<sup>fm+</sup> ILCs may shape the tumor microenvironment in a way that it is more conducive for other immune effector cells to invade. Similar to LTi's, we found high levels of the chemokine receptors CCR2, CCR6, CCR7, CCR8, and CXCR5 in splenic *Rorc*<sup>fm+</sup> ILCs, compared with siLP *Rorc*<sup>fm+</sup> ILCs (Fig. 7 A), suggesting an involvement of ILCs in the formation of lymphoid structures (Shields et al., 2010). Along that line, splenic *Rorc*<sup>fm+</sup> ILCs showed an activated phenotype, indicated by greater expression levels of MHC II, CD74, and CD28 compared with siLP *Rorc*<sup>fm+</sup> ILCs (Fig. S5 B). To further analyze the tumor microenvironment and the pattern of tumor-infiltrating immune cells, we coinjected B16–IL-12 tumor cells with splenic and siLP *Rorc*<sup>fm+</sup> ILCs 10 d after tumor inoculation by high-dimensional, 22-parameter flow cytometry. Unbiased, algorithm-driven analysis revealed differences in the tumor-infiltrating immune compartments of splenic *Rorc*<sup>fm+</sup> ILCs compared with the other experimental groups (Fig. 7, B and C), characterized by increased invasion by CD8<sup>+</sup> T cells, NK cells, and NKT cells, as well as by activated myeloid cells (Fig. 7 D). Interestingly, all these cell types have previously been shown to be involved in tumor suppression driven by IL-12 (Kerker et al., 2011; Tugues et al., 2015) and might cooperate to provide an efficient IL-12-driven antitumor response through *Rorc*<sup>fm+</sup> ILCs. Taken together, our results suggest a preferential recruitment of lymphoid-tissue-derived *Rorc*<sup>fm+</sup> ILCs to the tumor site, which, in turn, may render the tumor microenvironment more conducive to the invasion of further immune effectors.

## DISCUSSION


Since the discovery of LTi's two decades ago, ILCs have been studied intensively and shown to be involved in tissue homeostasis and host defense (Artis and Spits, 2015; Eberl et al., 2015; Sonnenberg and Artis, 2015). It is becoming increasingly clear that ILCs affect tumor immune surveillance (Eisenring et al., 2010; Ikutani et al., 2012; Kirchberger et al., 2013; Chan et al., 2014; Jovanovic et al., 2014; Li et al., 2014; Crome et al., 2017; Irshad et al., 2017). The function of ILCs varies depending on the tumor model and tissue localization, raising questions as to how the tissue microenvironment influences these cells and especially their function. Here, we show that ILC3s adapt to their local tissue microenvironment and demonstrate vastly

different phenotypic characteristics (i.e., marker expression). Their functional properties (i.e., tumor suppression), however, are guided by their ontogeny (i.e., early transcriptional imprinting) as well as by adaptation to their tissue microenvironment, uncoupled from their phenotype.

Although the development of ILC3s has been elucidated in various studies (Satoh-Takayama et al., 2010; Cherrier et al., 2012; Constantinides et al., 2014; Klose et al., 2014; Montaldo et al., 2014), the effect of the tissue microenvironment on their phenotype and function remains largely elusive. Notably, our computer-aided dimensionality reduction and clustering showed a clearly demarcated specification for ILC3s in lymphoid and nonlymphoid organs. Parabiosis experiments demonstrated that ILCs are tissue-resident cells (Gasteiger et al., 2015); only a few of them have been found in the circulation, suggesting distinct phenotypes and functions for these cells in different tissues. Moreover, the expression of homing markers, such as  $\alpha 4\beta 7$ , CXCR6, CCR9, and CCR7 (Hoyler et al., 2012; Chea et al., 2015; Kim et al., 2015; Mackley et al., 2015), in ILCs and ILC precursors indicates a differential recruitment into tissues or lesions. We found ILC3s to distribute among various organs in the steady state and to phenotypically adapt to their new tissue environment, regardless of their origin. Hence, the phenotypic properties of ILC3s are not invariably imprinted during early development but are acquired upon homing to new localizations. In line with our findings, two previous studies demonstrated that a considerable part of intestinal *Rorc*<sup>fm+</sup> ILCs lose ROR $\gamma$ t expression when homing to colon lamina propria or spleen (Vonarbourg et al., 2010) and that the transcription factor was reexpressed when “inflammatory” ILC1s reconverted to “homeostatic” IL-22-producing ILC3s in the small intestine after adoptively transferring into *Rag2*<sup>-/-</sup>*IL2R $\gamma$* <sup>-/-</sup> mice (Bernink et al., 2015). Taken together, these findings suggest that the tissue microenvironment in the steady state provides strong guidance cues for the phenotypic adaptation of ILC3s to an individual tissue. Although this hints toward the high plasticity of ILCs, single cell-tracing experiments would be necessary to fully exclude heterogeneity of the transferred ILC population, as well as a differential maturation status or the presence of potential precursor cells that might undergo tissue-specific maturation or differentiation.

How the splenic and siLP microenvironments drive *Rorc*<sup>fm+</sup> cells to predominantly ILC1/NK cells or ILC3 phenotypes remains unclear. This dichotomy might be ex-

(D) *Il12rb2*<sup>-/-</sup> mice were s.c. challenged with B16–IL-12 coinjected with splenic (spl) *Rorc*<sup>fm+</sup> ILCs (open circles), *Eomes*<sup>-</sup> ILC1s (open squares), *Eomes*<sup>+</sup> NK cells (closed squares), or in the absence of ILCs (closed circles), and tumor growth was measured over time. Graphs represent pooled data from two independent experiments,  $n \geq 5$  each (means  $\pm$  SEM). For comparison of the tumor growth curve, two-way ANOVA with Tukey's multiple comparisons test was used. \*\*\*,  $P < 0.001$ . (E) Quantification of tumor burden 21 d after tumor inoculation. Graphs represent pooled data from two independent experiments,  $n \geq 5$  each (means  $\pm$  SEM). One-way ANOVA with Tukey's multiple comparisons test was performed. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ . (F) PCA of different ILC subsets, including splenic NK cells, ILC1s, and *Rorc*<sup>fm+</sup> ILC3s as well as siLP *Rorc*<sup>fm+</sup> ILC3s. (G) Heat map of differentially expressed genes of splenic NK cells, ILC1s and (*Rorc*<sup>fm+</sup>) ILC3s as well as siLP (*Rorc*<sup>fm+</sup>) ILC3s. (H) Heat maps of differentially expressed genes clustered to the indicated category. Heat maps show representative data of one sample per group.



**Figure 7. Splenic *Rorc*<sup>f/m+</sup> ILCs render the tumor microenvironment more conducive to immune cell invasion.** (A) Chemokine receptor expression by the different splenic and siLP *Rorc*<sup>f/m+</sup> ILCs; data from NGS (means ± SD; Fig. 6). One-way ANOVA with Tukey's multiple comparisons test was performed. \*\*, P < 0.01; \*\*\*, P < 0.001. (B) Dimensionality reduction using t-SNE. Data from tumor-infiltrating immune cells of B16-IL-12 tumors (day 10) coinjected with siLP, splenic (spl) *Rorc*<sup>f/m+</sup> ILCs, or without ILCs (gated on live, single CD45<sup>+</sup>) were transformed and plotted in two t-SNE dimensions using R software.

plained by the differential functions between both organs—the lymphoid organs representing a “sterile” environment and a site of antigen presentation, whereas the intestine is a barrier tissue highly colonized by commensal bacteria. Cytokines, such as IL-23 and IL-1 $\beta$  or IL-12, for example, have been shown to induce the ILC3 and the ILC1 phenotypes, respectively (Vonarbourg et al., 2010; Bernink et al., 2015). Accordingly, we and others found that splenic *Rorc*<sup>flm+</sup> ILCs expressed higher levels of the IL-12–specific receptor subunit *Il12 $\beta$ 2* compared with siLP *Rorc*<sup>flm+</sup> ILCs, whereas the latter population expresses the IL-23 receptor and higher amounts of IL-1 $\beta$  receptor. Moreover, mice deficient for *IL12a* were found to have increased numbers of ROR $\gamma$ <sup>+</sup>NCR<sup>-</sup> ILC3s (Vonarbourg et al., 2010).

In addition to cytokines, commensal bacteria, metabolic products, and the dominating cell types populating the different tissues may regulate the phenotypic properties of ILC3s. For example, the gut metabolite retinoic acid was found to induce the conversion of CD127<sup>+</sup> ILC1 to IL-22–producing ILC3 (Bernink et al., 2015). CX3CR1<sup>+</sup> mononuclear phagocytes/intestinal DCs that develop in the intestine after commensal colonization drive the production of IL-22 by ROR $\gamma$ <sup>+</sup> ILCs (Niess and Adler, 2010; Manta et al., 2013; Satoh-Takayama et al., 2014). Further, commensal bacteria might be able to stimulate ILCs directly by engaging NCRs, such as NKp46 or NKp44, in human or mouse, respectively (Esin et al., 2008; Chaushu et al., 2012; Glatzer et al., 2013).

*Rorc*<sup>flm+</sup> ILCs, more precisely LTi's, are implicated in the organogenesis of lymphoid structures, thus having a constructive or organizational character. In addition, they may interfere with the establishment of the tumor tissue itself or tumor-associated lymphoid structures. High lymphocyte infiltration (recruited by chemokines such as CCL21) and a tumor landscape resembling lymphoid structures have been suggested to be beneficial for tumor suppression (Messina et al., 2012). Early after B16 inoculation, IL-12 led to the up-regulation of chemokines (such as CCL2, CCL3, CCL4, CCL5, CXCR9, and CXCR10; unpublished data) that are also associated with LN-like structures in human melanoma, pointing toward successful tumor suppression. Of those, CCL2 and CCL5, expressed in the tumor microenvironment, were previously shown to correlate with lymphocyte infiltration and tumor destruction (Balkwill, 2004). Whether IL-12–responsive ILC3s also induce lymphoid-like structures in our tumor setting will require further investigation, but the presence of NCR<sup>+</sup> ILC3s has been correlated with increased lymphoid structures and beneficial clinical outcome in patients with human lung cancers (Carrega et al., 2015), suggesting that *Rorc*<sup>flm+</sup> ILCs

have a role at the tumor–immune interphase in preclinical models and patients alike.

We show that the tumor-suppressive properties of *Rorc*<sup>flm+</sup> ILCs are shaped not only during their lineage commitment but also by the tissue microenvironment. As such, lymphoid tissue–derived *Rorc*<sup>flm+</sup> ILCs are sensitive to IL-12 and suppress tumor growth, whereas intestinal *Rorc*<sup>flm+</sup> ILCs fail to do so. In contrast, ILCs that mainly reside in mucosal barrier tissues engage the IL-23/IL-17 axis to protect against invading pathogens and have been reported to drive gut tumorigenesis (Chan et al., 2014). Collectively, these studies demonstrate how powerful the tissue microenvironment effects on *Rorc*<sup>flm+</sup> ILCs are and how it shapes them along the IL-12/IL-23 axis toward a pro- or antitumorigenic response (Eisenring et al., 2010; Chan et al., 2014).

Even though the cellular tissue origin of tumor-suppressive ILCs remains unknown, our data suggest that they might arise from the lymphatic system, where they promptly react to and/or initiate a type 1 immune response. A recent study showed active migration of ILCs in response to CCR7 and CCR9 (Mackley et al., 2015), indicating that ILCs actively migrate to certain tissues upon triggering of homing receptors. In our setting of IL-12–mediated tumor suppression, *Rorc*<sup>flm+</sup> ILCs are recruited to the tumor tissue, in all likelihood, responding to specific chemokines present in the activated tumor tissue. Once *Rorc*<sup>flm+</sup> ILCs are present in the tumor, they render the tumor microenvironment more conducive to the invasion of immune effectors, potentially activating the adaptive immune system and/or, as previously hypothesized, by potentiating the crosstalk between innate and adaptive antitumor immune responses.

The effect of IL-12–induced plasticity and the tissue microenvironment on the phenotype and function of ILCs seems undisputable (Cella et al., 2010; Vonarbourg et al., 2010; Klose et al., 2013, 2014; Huang et al., 2014; Bernink et al., 2015; Bal et al., 2016; Lim et al., 2016; Ohne et al., 2016) and justifies further analysis of the mechanism by which ILCs can alter the tumor microenvironment. Moreover, we show a convergence of ontogeny, phenotype, and function, suggesting that classification of ILC subsets based on their phenotypic properties seems unreliable because ILCs are guided primarily by their ontogeny (i.e., transcriptional regulation) and the tissue they reside in.

## MATERIALS AND METHODS

### Study design

Our aim was to study the effect of the tissue microenvironment and ontogeny on the phenotype and function of ILC3s by investigating their tumor-suppressive capacity. We

---

Clustering was performed using the flowSOM algorithm ( $k = 8$ ). Depicted are an annotated, combined data set (top) and the data sets of tumor-infiltrating immune cells of tumors coinjected with siLP *Rorc*<sup>flm+</sup> ILCs (left), splenic *Rorc*<sup>flm+</sup> ILCs (middle), and without ILCs (right). (C) Lymphocyte and myeloid-associated markers plotted in a heat map across flowSOM clusters from B. (D) Quantification of the altered cell populations identified in B using manual gating. Graphs represent pooled data from two independent experiments,  $n \geq 5$  each (means  $\pm$  SEM). \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ .

used several genetically modified mouse models for tumor experiments and to distinguish various ILC3 and ILC1 subsets. Age- and sex-matched mice were randomly divided into experimental groups. Experiments to characterize the phenotype and determine the function of ILC3s were performed at least two times with three to eight mice per group. All animal care and handling were performed according to the guidelines by the Swiss cantonal veterinary office.

### Mice

Mice were housed in individually ventilated cages under specific pathogen-free conditions. Conventional C57BL/6 mice (*WT*) were purchased from Janvier Labs. *Il12rb2<sup>-/-</sup>*, *Rag1<sup>-/-</sup>*, *Rag2<sup>-/-</sup>Il2rg<sup>-/-</sup>*, and *Rorc<sup>GFP/+</sup>* (*Rorc<sup>-/-</sup>*) mice were purchased from The Jackson Laboratory. *Il15ra<sup>-/-</sup>* mice were provided by S. Bulfone-Paus (Forschungszentrum Borstel, Borstel, Germany); *Rorc-eYFP* and *Rorc<sup>cre</sup>* mice by A. Diefenbach (University of Mainz, Mainz, Germany); and *Eomes<sup>GFP/+</sup>* mice by S.J. Arnold (University of Freiburg, Freiburg, Germany; Arnold et al., 2009). All experimental procedures were performed according to the animal licenses approved by the Swiss cantonal veterinary office (licenses 145/2012 and 142/2015).

### Tumor cell lines

B16.F10 melanoma cells were purchased from ATCC. The generation of tumor cell lines stably producing IL-12:Fc or Fc has been previously described (Eisenring et al., 2010). B16 tumor cells were cultured in DMEM (PAN-Biotech) supplemented with 10% FBS (Biochrom), 1% glutamine (Gibco), 1% sodium-pyruvate (Gibco), and 1% penicillin-streptomycin (Invitrogen; hereafter, referred to as complete medium). Transfected cell lines were selected with hygromycin B (Invitrogen) and maintained at 37°C, 5% CO<sub>2</sub>.

### Tumor transplantation and monitoring

A total of  $2 \times 10^5$  tumor cells were s.c. injected into the lateral abdomen of the mouse. Tumor growth was measured three times a week. Animals that showed clinical symptoms, such as apathy, severe hunchback posture, weight loss of >20% of peak weight, and/or tumor ulceration were euthanized.

### IL-12 treatment

IL-12:Fc (IL-12) was administered systemically i.p. or local intratumoral, at a dose of 200 µg three times a week. Production and purification of mouse IL-12:Fc (IL-12) was performed as previously described (vom Berg et al., 2013).

### Lymphocyte isolation

Mice were sacrificed by CO<sub>2</sub> inhalation, perfused with 25 ml ice-cold PBS, and organs were harvested and processed as follows. Lymphoid organs were digested in 0.4 mg/ml collagenase IV (from *Clostridium histolyticum*; Sigma-Aldrich) in HBSS, including MgCl<sub>2</sub> and CaCl<sub>2</sub> (Gibco) supplemented with 10% FBS for 30 min at 37°C and agitated. The lung

and the liver tissues were digested using 1 mg/ml collagenase IV. For liver samples, a Percoll gradient was performed (continuous gradient, 27%; GE Healthcare). The colon and small intestine were digested as described before (Burkhard et al., 2014). The skin and tumor tissue were isolated using 1 mg/ml collagenase IV and 0.2 mg/ml DNase I (Sigma-Aldrich) for 1 h at 37°C and agitating.

### Flow cytometry and cell sorting

Single-cell suspensions were stained for 20–30 min at 4°C in PBS. Fluorochrome-conjugated antibodies specific against mouse c-KIT (2B8), CCR6 (29-2L17), CD103 (2E7), CD11c (N418, HL3), CD19 (6D5, 1D3), CD27 (LG.3A10), CD3 (145-2C44), CD4 (GK1.5, RM4-5), CD45 (30-F11), CD49b (DX5), CD5 (53-7.3), Eomes (Dan11mag), GM-CSF (MP1-22E9), IFN-γ (XMG1.2), IL-17 (TC11-18H10), IL-7Rα (A7R34, SB/199), NK1.1 (PK136), NKp46 (29A1.4), RORγt (Q31-378), Sca-1 (D7), T-bet (4B10), TCRβ (H57-597), and Thy1.2 (30-H12, OX-7) were purchased from BioLegend, BD, or eBioscience. In all staining, dead cells were excluded using Live/Dead fixable staining reagents (Invitrogen), and doublets were excluded by FSC-A versus FSC-H and SSC-A versus SSC-H gating. Samples were acquired using a FACSCanto II, LSR Fortessa II, or FACSsymphony flow cytometer and FACSDiva software (BD). Cell sorting was performed on a FACS Aria III (BD) using a 70-µm nozzle, with a purity of >95%. Data analysis was performed using FlowJo 10.0.8 software (Tree Star). For some graphs, data from several individual samples were concatenated in FlowJo.

### In vitro stimulation and intracellular staining

For cytokine staining, cells were stimulated for 4 h at 37°C in complete RPMI with 0.05 µg/ml PMA, 0.5 µg/ml ionomycin, and 1 µl/ml brefeldin A (GolgiPlug; Invitrogen). Intracellular staining was performed using the Cytofix/Cytoperm kit (BD) or the Foxp3/transcription factor staining buffer set (eBioscience), according to manufacturer's instructions with the respective antibodies at 4°C for 30–60 min or overnight.

### Automated population identification in high-dimensional data analysis and t-SNE dimensionality reduction

After preprocessing of the flow cytometric data gating on live, single CD45<sup>+</sup> *Rorc<sup>fm+</sup>* (YFP<sup>+</sup>) ILCs, flow cytometry standard (.fcs) files of splenic and siLP *Rorc<sup>fm+</sup>* ILCs were down-sampled to  $4 \times 10^4$  events per sample and combined into one file. FlowSOM clustering algorithm was used to identify biologically meaningful clusters in an unbiased way using R software, and the created nodes were subjected to meta-clustering. The flowSOM algorithm clusters cells with similar phenotypic appearance into subpopulations or subsets, which are depicted in special proximity on the t-SNE plot (Levine et al., 2015; Van Gassen et al., 2015). To identify meaningful ILC subsets, based on knowledge of the literature, a *k*-value of 5 was chosen. Heat maps were drawn using the ggplot2 R package to display median expression levels

for the indicated clusters. Dendrograms were calculated using hierarchical clustering. To visualize the high-dimensional data and clusters, two-dimensional t-SNE plots were created using R software and were overlaid with the clusters created by the FlowSOM algorithm.

### RNA isolation and quantitative RT-PCR

RNA isolation was conducted using the RNeasy Mini Plus or Micro Plus Kits (QIAGEN). First-strand cDNA synthesis was performed using Superscript II reverse transcription (Invitrogen) and oligo (dT) priming (PeproTech), according to the manufacturers' protocols.

Quantitative analysis was conducted using a SYBR Green master mix (Roche). The PCR reaction was performed with a C1000 Touch thermal cycler (Bio-Rad Laboratories). For analysis, cycle threshold values of the genes of interest were normalized to the values of the polymerase 2 (Pol2) gene (as housekeeping gene). Primers used were IL12rb2 (forward): 5'-TGTGGGGTGGAGATCTCAGT-3'; IL12rb2 (reverse): 5'-TCTCCTTCTGGACACATGA-3'; IL-23r (forward): 5'-CCAAGTATATTGTGCATGTGAAGA-3'; IL-23r (reverse): 5'-AGCTTGAGGCAAGATATTGTTGT-3'; Pol2 (forward): 5'-CTGGTCCTTCGAATCCGCATC-3'; Pol2 (reverse): 5'-GCTCGATACCCTGCAGGGTCA-3'.

### NGS

For NGS, tumor tissue was resected 5 d after tumor inoculation and was immediately transferred into RNAlater stabilization solution (Ambion). For total RNA isolation, the tumor tissue was homogenized using a tissue homogenizer (Omni International), and total RNA was extracted using the RNeasy Micro Kit Plus (QIAGEN) according to the manufacturer's instructions. NGS was performed by the Functional Genomic Center Zurich (<http://www.fgcz.ch>) using the HiSeq 2500 v4 System (Illumina). Quality control included the fastqc and DESeq2 analysis. The GO pathway analysis of tumor tissues was performed using the MetaCore software (Thomson Reuters), and visualization was performed with the TM4 MultiExperiment Viewer (Saeed et al., 2003). Pathway analysis of differentially expressed genes in splenic *Rorc*<sup>flm+</sup> ILCs versus splenic *Eomes*<sup>-</sup> ILC1s, *Eomes*<sup>+</sup> NK cells and siLP *Rorc*<sup>flm+</sup> ILCs (based on Fig. S3) using David Bioinformatics Resources to extract GO terms "BP" (biological process) and "ReViGo" for visualization of the false discovery rate: Benjamini-Hochberg  $\leq 0.01$ . PCA was performed using Matlab 2014b (MathWorks).

### Statistical analysis

To analyze data statistically, GraphPad Prism 6.0 software (GraphPad Software) was used. A two-tailed unpaired *t* test was performed to determine statistical significance between two groups. Welch's correction was applied in case of significantly different variances. For three or more groups, one-way ANOVA with Tukey's multiple comparisons test was performed. For comparison of the tumor growth curve two-way

ANOVA with Tukey's multiple comparisons test was used; *p*-values  $< 0.05$  were considered significantly different (exact *p*-values indicated in figure legends). Data are displayed as means  $\pm$  SEM, unless otherwise stated.

### Online supplemental material

Fig. S1 shows that *Rorc*<sup>flm+</sup> ILCs from various organs possess different expression patterns. Fig. S2 shows that lymphoid *Rorc*<sup>flm+</sup> ILCs suppress tumor growth, whereas nonlymphoid *Rorc*<sup>flm+</sup> ILCs fail to do so. Fig. S3 shows a schematic representation of *Rorc* fate map crossed to *Eomes* reporter mice, which allows identification of type 1 and type 3 ILC subsets (gating strategy). Fig. S4 NGS reveals differentially expressed genes by splenic *Rorc*<sup>flm+</sup> ILCs compared with other ILC subsets. Fig. S5 shows splenic *Rorc*<sup>flm+</sup> ILCs only express low amounts of cytotoxic molecules and an activated phenotype.

### ACKNOWLEDGMENTS

We thank Sabrina Nemetz, Jennifer Jaberg, Mirjam Lutz, and the Flow Cytometry Facility, University of Zurich for technical assistance.

This study was supported by grants from the Swiss National Science Foundation (SNSF; grants 316030-150768, 310030-146130, and CRS I13-136203 to B. Becher), European Community FP7 (grant no. 602239 [ATECT] to B. Becher), and the University Priority Research Project (URPP) Translational Cancer Research (to B. Becher). K. Nussbaum holds a fellowship from Boehringer Ingelheim Fonds. S.J. Arnold is supported by the Deutsche Forschungsgemeinschaft (DFG AR732/1-1 and CRC 850, project A3). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

The authors declare no competing financial interests.

Author contributions: K. Nussbaum, S.H. Burkhard, and B. Becher designed the research; K. Nussbaum, S.H. Burkhard, I. Ohs, F. Mair, and S. Tugues performed and/or analyzed the data. C.S.N. Klose and A. Diefenbach provided mice and helped to interpret the data, S.J. Arnold provided mice, and K. Nussbaum, S. Tugues, and B. Becher wrote the manuscript.

Submitted: 2 December 2016

Revised: 11 April 2017

Accepted: 9 June 2017

### REFERENCES

- Arnold, S.J., J. Sugnaseelan, M. Groszer, S. Srinivas, and E.J. Robertson. 2009. Generation and analysis of a mouse line harboring GFP in the *Eomes/Tbr2* locus. *Genesis*. 47:775-781. <http://dx.doi.org/10.1002/dvg.20562>
- Artis, D., and H. Spits. 2015. The biology of innate lymphoid cells. *Nature*. 517:293-301. <http://dx.doi.org/10.1038/nature14189>
- Bal, S.M., J.H. Bernink, M. Nagasawa, J. Groot, M.M. Shikhagaie, K. Golebski, C.M. van Drunen, R. Lutter, R.E. Jonkers, P. Hombrink, et al. 2016. IL-1 $\beta$ , IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs. *Nat. Immunol.* 17:636-645. <http://dx.doi.org/10.1038/ni.3444>
- Balkwill, F. 2004. Cancer and the chemokine network. *Nat. Rev. Cancer*. 4:540-550. <http://dx.doi.org/10.1038/nrc1388>
- Bernink, J.H., L. Krabbendam, K. Germar, E. de Jong, K. Gronke, M. Kofoed-Nielsen, J.M. Munneke, M.D. Hazenberg, J. Villaudy, C.J. Buskens, et al. 2015. Interleukin-12 and -23 control plasticity of CD127<sup>+</sup> group 1 and

- group 3 innate lymphoid cells in the intestinal lamina propria. *Immunity*. 43:146–160. <http://dx.doi.org/10.1016/j.immuni.2015.06.019>
- Bie, Q., P. Zhang, Z. Su, D. Zheng, X. Ying, Y. Wu, H. Yang, D. Chen, S. Wang, and H. Xu. 2014. Polarization of ILC2s in peripheral blood might contribute to immunosuppressive microenvironment in patients with gastric cancer. *J. Immunol. Res.* 2014:923135. <http://dx.doi.org/10.1155/2014/923135>
- Burkhard, S.H., F. Mair, K. Nussbaum, S. Hasler, and B. Becher. 2014. T cell contamination in flow cytometry gating approaches for analysis of innate lymphoid cells. *PLoS One*. 9:e94196. <http://dx.doi.org/10.1371/journal.pone.0094196>
- Carrega, P., F. Loiacono, E. Di Carlo, A. Scaramuccia, M. Mora, R. Conte, R. Benelli, G.M. Spaggiari, C. Cantoni, S. Campana, et al. 2015. NCR<sup>+</sup> ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures. *Nat. Commun.* 6:8280. <http://dx.doi.org/10.1038/ncomms9280>
- Cella, M., K. Otero, and M. Colonna. 2010. Expansion of human NK-22 cells with IL-7, IL-2, and IL-1 $\beta$  reveals intrinsic functional plasticity. *Proc. Natl. Acad. Sci. USA*. 107:10961–10966. <http://dx.doi.org/10.1073/pnas.1005641107>
- Chan, I.H., R. Jain, M.S. Tessmer, D. Gorman, R. Mangadu, M. Sathe, F.Vives, C. Moon, E. Penaflor, S. Turner, et al. 2014. Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells. *Mucosal Immunol.* 7:842–856. <http://dx.doi.org/10.1038/mi.2013.101>
- Chaushu, S., A. Wilensky, C. Gur, L. Shapira, M. Elboim, G. Halftek, D. Polak, H. Achdout, G. Bachrach, and O. Mandelboim. 2012. Direct recognition of Fusobacterium nucleatum by the NK cell natural cytotoxicity receptor NKp46 aggravates periodontal disease. *PLoS Pathog.* 8:e1002601. <http://dx.doi.org/10.1371/journal.ppat.1002601>
- Chea, S., C. Pissot, T. Perchet, M. Petit, A. Cumano, and R. Golub. 2015. CXCR6 expression is important for retention and circulation of ILC precursors. *Mediators Inflamm.* 2015:368427. <http://dx.doi.org/10.1155/2015/368427>
- Cherrier, M., S. Sawa, and G. Eberl. 2012. Notch, Id2, and ROR $\gamma$ t sequentially orchestrate the fetal development of lymphoid tissue inducer cells. *J. Exp. Med.* 209:729–740. <http://dx.doi.org/10.1084/jem.20111594>
- Constantinides, M.G., B.D. McDonald, P.A. Verhoef, and A. Bendelac. 2014. A committed precursor to innate lymphoid cells. *Nature*. 508:397–401. <http://dx.doi.org/10.1038/nature13047>
- Crome, S.Q., L.T. Nguyen, S. Lopez-Verges, S.Y.C. Yang, B. Martin, J.Y. Yam, D.J. Johnson, J. Nie, M. Pniak, P.H. Yen, et al. 2017. A distinct innate lymphoid cell population regulates tumor-associated T cells. *Nat. Med.* 23:368–375. <http://dx.doi.org/10.1038/nm.4278>
- Eberl, G., and D.R. Littman. 2004. Thymic origin of intestinal  $\alpha\beta$  T cells revealed by fate mapping of ROR $\gamma$ <sup>+</sup> cells. *Science*. 305:248–251. <http://dx.doi.org/10.1126/science.1096472>
- Eberl, G., M. Colonna, J.P. Di Santo, and A.N.J. McKenzie. 2015. Innate lymphoid cells: A new paradigm in immunology. *Science*. 348:aaa6566. <http://dx.doi.org/10.1126/science.aaa6566>
- Eisenring, M., J. vom Berg, G. Kristiansen, E. Saller, and B. Becher. 2010. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. *Nat. Immunol.* 11:1030–1038. <http://dx.doi.org/10.1038/ni.1947>
- Esin, S., G. Batoni, C. Counoupas, A. Stringaro, F.L. Brancatisano, M. Colone, G. Maisetta, W. Florio, G. Arancia, and M. Campa. 2008. Direct binding of human NK cell natural cytotoxicity receptor NKp44 to the surfaces of mycobacteria and other bacteria. *Infect. Immun.* 76:1719–1727. <http://dx.doi.org/10.1128/IAI.00870-07>
- Finke, D., H. Acha-Orbea, A. Mattis, M. Lipp, and J. Kraehenbuhl. 2002. CD4<sup>+</sup>CD3<sup>+</sup> cells induce Peyer's patch development: role of  $\alpha\beta$ 1 integrin activation by CXCR5. *Immunity*. 17:363–373. [http://dx.doi.org/10.1016/S1074-7613\(02\)00395-3](http://dx.doi.org/10.1016/S1074-7613(02)00395-3)
- Fuchs, A., and M. Colonna. 2013. Innate lymphoid cells in homeostasis, infection, chronic inflammation and tumors of the gastrointestinal tract. *Curr. Opin. Gastroenterol.* 29:581–587. <http://dx.doi.org/10.1097/MOG.0b013e328365d339>
- Fukuyama, S., T. Hiroi, Y. Yokota, P.D. Rennert, M. Yanagita, N. Kinoshita, S. Terawaki, T. Shikina, M. Yamamoto, Y. Kurono, and H. Kiyono. 2002. Initiation of NALT organogenesis is independent of the IL-7R, LT $\beta$ R, and NIK signaling pathways but requires the Id2 gene and CD3<sup>+</sup>CD4<sup>+</sup>CD45<sup>+</sup> cells. *Immunity*. 17:31–40. [http://dx.doi.org/10.1016/S1074-7613\(02\)00339-4](http://dx.doi.org/10.1016/S1074-7613(02)00339-4)
- Gasteiger, G., X. Fan, S. Dikiy, S.Y. Lee, and A.Y. Rudensky. 2015. Tissue residency of innate lymphoid cells in lymphoid and non-lymphoid organs. *Science*. 350:981–985. <http://dx.doi.org/10.1126/science.aac9593>
- Glatzer, T., M. Killig, J. Meisig, I. Ommert, M. Luetke-Eversloh, M. Babic, D. Paclik, N. Blüthgen, R. Seidl, C. Seifarth, et al. 2013. ROR $\gamma$ t<sup>+</sup> innate lymphoid cells acquire a proinflammatory program upon engagement of the activating receptor NKp44. *Immunity*. 38:1223–1235. <http://dx.doi.org/10.1016/j.immuni.2013.05.013>
- Goto, Y., T. Obata, J. Kunisawa, S. Sato, I.I. Ivanov, A. Lamichhane, N. Takeyama, M. Kamioka, M. Sakamoto, T. Matsuki, et al. 2014. Innate lymphoid cells regulate intestinal epithelial cell glycosylation. *Science*. 345:1254009. <http://dx.doi.org/10.1126/science.1254009>
- Hepworth, M.R., T.C. Fung, S.H. Masur, J.R. Kelsen, F.M. McConnell, J. Dubrot, D.R. Withers, S. Hugues, M.A. Farrar, W. Reith, et al. 2015. Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4<sup>+</sup> T cells. *Science*. 348:1031–1035. <http://dx.doi.org/10.1126/science.aaa4812>
- Hoyler, T., C.S.N. Klose, A. Souabni, A. Turqueti-Neves, D. Pfeifer, E.L. Rawlins, D. Voehringer, M. Busslinger, and A. Diefenbach. 2012. The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. *Immunity*. 37:634–648. <http://dx.doi.org/10.1016/j.immuni.2012.06.020>
- Huang, Y., L. Guo, J. Qiu, X. Chen, J. Hu-Li, U. Siebenlist, P.R. Williamson, J.F. Urban, and W.E. Paul. 2014. IL-25-responsive, lineage-negative KLRG1<sup>hi</sup> cells are multipotential “inflammatory” type 2 innate lymphoid cells. *Nat. Immunol.* 16:161–169. <http://dx.doi.org/10.1038/ni.3078>
- Ikutani, M., T. Yanagibashi, M. Ogasawara, K. Tsuneyama, S. Yamamoto, Y. Hattori, T. Kouro, A. Itakura, Y. Nagai, S. Takaki, and K. Takatsu. 2012. Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity. *J. Immunol.* 188:703–713. <http://dx.doi.org/10.4049/jimmunol.1101270>
- Irshad, S., F. Flores-Borja, K. Lawler, J. Monypenny, R. Evans, V. Male, P. Gordon, A. Cheung, P. Gazinska, F. Noor, et al. 2017. ROR $\gamma$ t<sup>+</sup> innate lymphoid cells promote lymph node metastasis of breast cancers. *Cancer Res.* 77:1083–1096. <http://dx.doi.org/10.1158/0008-5472.CAN-16-0598>
- Jovanovic, I.P., N.N. Pejnovic, G.D. Radosavljevic, J.M. Pantic, M.Z. Milovanovic, N.N. Arsenijevic, and M.L. Lukic. 2014. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. *Int. J. Cancer*. 134:1669–1682. <http://dx.doi.org/10.1002/ijc.28481>
- Kerkar, S.P., R.S. Goldszmid, P. Muranski, D. Chinnsamy, Z. Yu, R.N. Reger, A.J. Leonardi, R.A. Morgan, E. Wang, F.M. Marincola, et al. 2011. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. *J. Clin. Invest.* 121:4746–4757. <http://dx.doi.org/10.1172/JCI58814>
- Kim, M.H., E.J. Taparowsky, and C.H. Kim. 2015. Retinoic acid differentially regulates the migration of innate lymphoid cell subsets to the gut. *Immunity*. 43:107–119. <http://dx.doi.org/10.1016/j.immuni.2015.06.009>



- Kirchberger, S., D.J. Royston, O. Boulard, E. Thornton, F. Franchini, R.L. Szabady, O. Harrison, and F. Powrie. 2013. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. *J. Exp. Med.* 210:917–931. <http://dx.doi.org/10.1084/jem.20122308>
- Klose, C.S., E.A. Kiss, V. Schwierzeck, K. Ebert, T. Hoyler, Y. d'Hargues, N. Göppert, A.L. Croxford, A. Waisman, Y. Tanriver, and A. Diefenbach. 2013. A T-bet gradient controls the fate and function of CCR6<sup>+</sup>RORγt<sup>+</sup> innate lymphoid cells. *Nature*. 494:261–265. <http://dx.doi.org/10.1038/nature11813>
- Klose, C.S.N., M. Flach, L. Möhle, L. Rogell, T. Hoyler, K. Ebert, C. Fabiunke, D. Pfeifer, V. Sexl, D. Fonseca-Pereira, et al. 2014. Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. *Cell*. 157:340–356. <http://dx.doi.org/10.1016/j.cell.2014.03.030>
- Levine, J.H., E.F. Simonds, S.C. Bendall, K.L. Davis, A.D. Amir, M.D. Tadmor, O. Litvin, H.G. Fienberg, A. Jager, E.R. Zunder, et al. 2015. Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis. *Cell*. 162:184–197. <http://dx.doi.org/10.1016/j.cell.2015.05.047>
- Li, J., N. Razumilava, G.J. Gores, S. Walters, T. Mizuochi, R. Mourya, K. Besho, Y.-H. Wang, S.S. Glaser, P. Shivakumar, and J.A. Bezerra. 2014. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. *J. Clin. Invest.* 124:3241–3251. <http://dx.doi.org/10.1172/JCI173742>
- Lim, A.I., S. Menegatti, J. Bustamante, L. Le Bourhis, M. Allez, L. Rogge, J.-L. Casanova, H. Yssel, and J.P. Di Santo. 2016. IL-12 drives functional plasticity of human group 2 innate lymphoid cells. *J. Exp. Med.* 213:569–583. <http://dx.doi.org/10.1084/jem.20151750>
- Mackley, E.C., S. Houston, C.L. Marriott, E.E. Halford, B. Lucas, V. Cerovic, K.J. Filbey, R.M. Maizels, M.R. Hepworth, G.F. Sonnenberg, et al. 2015. CCR7-dependent trafficking of RORγt<sup>+</sup> ILCs creates a unique microenvironment within mucosal draining lymph nodes. *Nat. Commun.* 6:5862. <http://dx.doi.org/10.1038/ncomms6862>
- Manta, C., E. Heupel, K. Radulovic, V. Rossini, N. Garbi, C.U. Riedel, and J.H. Niess. 2013. CX<sub>3</sub>CR1<sup>+</sup> macrophages support IL-22 production by innate lymphoid cells during infection with *Citrobacter rodentium*. *Mucosal Immunol.* 6:177–188. <http://dx.doi.org/10.1038/mi.2012.61>
- Mchedlidze, T., M. Waldner, S. Zopf, J. Walker, A.L. Rankin, M. Schuchmann, D. Voehringer, A.N.J. McKenzie, M.F. Neurath, S. Pflanz, and S. Wirtz. 2013. Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. *Immunity*. 39:357–371. <http://dx.doi.org/10.1016/j.immuni.2013.07.018>
- Messina, J.L., D.A. Fenstermacher, S. Eschrich, X. Qu, A.E. Berglund, M.C. Lloyd, M.J. Schell, V.K. Sondak, J.S. Weber, and J.J. Mulé. 2012. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? *Sci. Rep.* 2:765. <http://dx.doi.org/10.1038/srep00765>
- Montaldo, E., L.G. Teixeira-Alves, T. Glatzer, P. Durek, U. Stervbo, W. Hamann, M. Babic, D. Paclik, K. Stölzel, J. Gröne, et al. 2014. Human RORγt<sup>+</sup>CD34<sup>+</sup> cells are lineage-specified progenitors of group 3 RORγt<sup>+</sup> innate lymphoid cells. *Immunity*. 41:988–1000. <http://dx.doi.org/10.1016/j.immuni.2014.11.010>
- Monticelli, L.A., G.F. Sonnenberg, M.C. Abt, T. Alenghat, C.G.K. Ziegler, T.A. Doering, J.M. Angelosanto, B.J. Laidlaw, C.Y. Yang, T. Sathiyawala, et al. 2011. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. *Nat. Immunol.* 12:1045–1054. <http://dx.doi.org/10.1038/ni.2131>
- Mortha, A., A. Chudnovskiy, D. Hashimoto, M. Bogunovic, S.P. Spencer, Y. Belkaid, and M. Merad. 2014. Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. *Science*. 343:1249288. <http://dx.doi.org/10.1126/science.1249288>
- Niess, J.H., and G. Adler. 2010. Enteric flora expands gut lamina propria CX<sub>3</sub>CR1<sup>+</sup> dendritic cells supporting inflammatory immune responses under normal and inflammatory conditions. *J. Immunol.* 184:2026–2037. <http://dx.doi.org/10.4049/jimmunol.0901936>
- Ohne, Y., J.S. Silver, L. Thompson-Snipes, M.A. Collet, J.P. Blanck, B.L. Cantarel, A.M. Copenhaver, A.A. Humbles, and Y.-J. Liu. 2016. IL-1 is a critical regulator of group 2 innate lymphoid cell function and plasticity. *Nat. Immunol.* 17:646–655. <http://dx.doi.org/10.1038/ni.3447>
- Saeed, A.I., V. Sharov, J. White, J. Li, W. Liang, N. Bhagabati, J. Braisted, M. Klapa, T. Currier, M. Thiagarajan, et al. 2003. TM4: a free, open-source system for microarray data management and analysis. *Biotechniques*. 34:374–378.
- Sanos, S.L., V.L. Bui, A. Mortha, K. Oberle, C. Heners, C. Johnner, and A. Diefenbach. 2009. RORγt and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46<sup>+</sup> cells. *Nat. Immunol.* 10:83–91. <http://dx.doi.org/10.1038/ni.1684>
- Satoh-Takayama, N., S. Lesjean-Pottier, P. Vieira, S. Sawa, G. Eberl, C.A.J. Vosshenrich, and J.P. Di Santo. 2010. IL-7 and IL-15 independently program the differentiation of intestinal CD3<sup>+</sup>NKp46<sup>+</sup> cell subsets from Id2-dependent precursors. *J. Exp. Med.* 207:273–280. <http://dx.doi.org/10.1084/jem.20092029>
- Satoh-Takayama, N., N. Serafini, T. Verrier, A. Rekiki, J.-C. Renaud, G. Frankel, and J.P. Di Santo. 2014. The chemokine receptor CXCR6 controls the functional topography of interleukin-22 producing intestinal innate lymphoid cells. *Immunity*. 41:776–788. <http://dx.doi.org/10.1016/j.immuni.2014.10.007>
- Shields, J.D., I.C. Kourtis, A.A. Tomei, J.M. Roberts, and M.A. Swartz. 2010. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. *Science*. 328:749–752. <http://dx.doi.org/10.1126/science.1185837>
- Silver, J.S., J. Kearley, A.M. Copenhaver, C. Sanden, M. Mori, L. Yu, G.H. Pritchard, A.A. Berlin, C.A. Hunter, R. Bowler, et al. 2016. Inflammatory triggers associated with exacerbations of COPD orchestrate plasticity of group 2 innate lymphoid cells in the lungs. *Nat. Immunol.* 17:626–635. <http://dx.doi.org/10.1038/ni.3443>
- Sonnenberg, G.F., and D. Artis. 2015. Innate lymphoid cells in the initiation, regulation and resolution of inflammation. *Nat. Med.* 21:698–708. <http://dx.doi.org/10.1038/nm.3892>
- Spits, H., D. Artis, M. Colonna, A. Diefenbach, J.P. Di Santo, G. Eberl, S. Koyasu, R.M. Locksley, A.N.J. McKenzie, R.E. Mebius, et al. 2013. Innate lymphoid cells—a proposal for uniform nomenclature. *Nat. Rev. Immunol.* 13:145–149. <http://dx.doi.org/10.1038/nri3365>
- Tugues, S., S.H. Burkhard, I. Ohs, M. Vrohings, K. Nussbaum, J. Vom Berg, P. Kulig, and B. Becher. 2015. New insights into IL-12-mediated tumor suppression. *Cell Death Differ.* 22:237–246. <http://dx.doi.org/10.1038/cdd.2014.134>
- Van Gassen, S., B. Callebaut, M.J. Van Helden, B.N. Lambrecht, P. Demeester, T. Dhaene, and Y. Saey. 2015. FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data. *Cytometry A*. 87:636–645. <http://dx.doi.org/10.1002/cyto.a.22625>
- vom Berg, J., M. Vrohings, S. Haller, A. Haimovici, P. Kulig, A. Sledzinska, M. Weller, and B. Becher. 2013. Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection. *J. Exp. Med.* 210:2803–2811. <http://dx.doi.org/10.1084/jem.20130678>
- Vonarbourg, C., A. Mortha, V.L. Bui, P.P. Hernandez, E.A. Kiss, T. Hoyler, M. Flach, B. Bengsch, R. Thimme, C. Hölscher, et al. 2010. Regulated expression of nuclear receptor RORγt confers distinct functional fates to NK cell receptor-expressing RORγt<sup>+</sup> innate lymphocytes. *Immunity*. 33:736–751. <http://dx.doi.org/10.1016/j.immuni.2010.10.017>